RUNX2 and osteosarcoma: RUNX2 expression was measured by immunohistochemistry and analyzed for correlations with clinical data in 105 osteosarcoma patients, and it appeared to be an independent predictor of metastasis-free survival and overall survival in a multivariate survival analysis.